This is the authors' abstract. We don't add key points for this paper.
// Matthieu Corvaisier 1 , Marjolaine Bauzone 1 , François Corfiotti 1, 2 , Florence Renaud 1, 3 , Mehdi El Amrani 1, 2 , Didier Monté 4 , Stéphanie Truant 1, 2 , Emmanuelle Leteurtre 1, 3 , Pierre Formstecher 1 , Isabelle Van Seuningen 1 , Christian Gespach 5, * , Guillemette Huet 1, 3, * 1 University Lille, Inserm, CHU Lille, UMR-S1172-JPARC-Jean-Pierre Aubert Research Center, F-59000, Lille, France 2 Department of Digestive Surgery and Transplantation, CHRU Lille, F-59000, Lille, France 3 Center of Biology-Pathology, CHRU Lille, F-59000, Lille, France 4 UMR8576 CNRS-Université de Lille Nord de France, F-59658, Villeneuve d'Ascq, France 5 INSERM U938, “Molecular and Clinical Oncology”, Hôpital Saint-Antoine, University Pierre et Marie Curie, F-75012, Paris, France * These authors contributed equally to this work Correspondence to: Guillemette Huet, email: guillemette.huet@inserm.fr Keywords: c-Myc, CREB, stemness, liver metastases, prognosis Received: May 20, 2016 Accepted: July 13, 2016 Published: August 04, 2016 ABSTRACT Our aim was to decipher the role and clinical relevance of the YAP/TAZ transcriptional coactivators in the regulation of the proliferation/quiescence balance in human colon cancer cells (CCC) and survival after 5FU-based chemotherapy. The prognostic value of YAP/TAZ on tumor relapse and overall survival was assessed in a five-year follow-up study using specimens of liver metastases ( n = 70) from colon cancer patients. In 5FU-chemoresistant HT29-5F31 and -chemosensitive HCT116 and RKO CCC, a reversible G0 quiescent state mediated by Cyclin E1 down-regulation was induced by 5FU in 5F31 cells and recapitulated in CCC by either YAP/TAZ or Cyclin E1 siRNAs or the YAP inhibitor Verteporfin. Conversely, the constitutive active YAPdc-S127A mutant restricted cellular quiescence in 5FU-treated 5F31 cells and sustained high Cyclin E1 levels through CREB Ser-133 phosphorylation and activation. In colon cancer patients, high YAP/TAZ level in residual liver metastases correlated with the proliferation marker Ki-67 ( p < 0.0001), high level of the YAP target CTGF ( p = 0.01), shorter disease-free and overall survival ( p = 0.008 and 0.04, respectively). By multivariate analysis and Cox regression model, the YAP/TAZ level was an independent factor of overall (Hazard ratio [CI 95%] 2.06 (1.02–4.16) p = 0.045) and disease-free survival (Hazard ratio [CI 95%] 1.98 (1.01–3.86) p = 0.045). Thus, YAP/ TAZ pathways contribute to the proliferation/quiescence switch during 5FU treatment according to the concerted regulation of Cyclin E1 and CREB. These findings provide a rationale for therapeutic interventions targeting these transcriptional regulators in patients with residual chemoresistant liver metastases expressing high YAP/TAZ levels.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Corvaisier et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: